{"ticker": {"uuid": "c97983dd-496f-4a92-8e26-ca6412001e86", "symbol": "CYC", "name": "Cyclopharm Limited", "exchange": "ASX", "country": "AU", "sector": "Healthcare", "industry": "Medical Distribution"}, "articles": [{"title": "Cyclopharm Ltd (ASX:CYC) Jumps 25.77% as Shares Reach AUD 0.61", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxNYnFxbDZOSjZEZWdhMEJyT2EzVlZwVVdJTmxPWXdsRjVHVmI0SjEtOF9HZGRZVHQ0bF9McWNDQ2kxd24wSHo2QjBnLUUtXy1ybVlLSnNCVG1VbExHZE1WVlljWE9pcWNVdTJKc3RfVXB5SGowQ1UwZlR2QmpOWkptTFRPMzdiUWV4OFh4MENmMGk0aVZIUVBVVjNzZw?oc=5", "source_name": "Kalkine", "published_at": "2026-07-15T10:09:00+00:00", "published_display": "15 Jul 2026 10:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Australia's Cyclopharm secures 11-site agreement in US", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxPQjRVLXptcldNc21RRm9KUVVvSklTSHg0blZQOHJqYUM5OXJRN3pPbDdiUUhtNnJZZVVEZ09VeUhMYWlvYzJwa19IQmdhdERWcDIxQkxjWkVGNklNQnJ5ZlYxeDQyT1Q2dF9RVkFHdmRfcFNWYk5WU1dBNm4yTzJtc3JPVDI5dWJkcmVkdk8xcHowQzRz?oc=5", "source_name": "grafa.com", "published_at": "2026-07-15T06:02:00+00:00", "published_display": "15 Jul 2026 06:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cyclopharm (ASX:CYC) locks in 11-site University Hospitals rollout with no staged delay", "summary": "", "url": "https://news.google.com/rss/articles/CBMifEFVX3lxTE1Fd3R6ZGdNbkNhY01xV3QzZjRwVXdMVGtleFlhdTNxV08yZU45aE03d1NqX3YzQmhqMFdraFZ6cUlBQmtnYmdCS0o0cHdFUlFqSm84T1VZbVozWWJSS2NIOVJSUzQ4dUg4Y1I3eUxSQktNMFRaUVlmSjluU0M?oc=5", "source_name": "Stocks Down Under", "published_at": "2026-07-15T00:21:25+00:00", "published_display": "15 Jul 2026 00:21", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cyclopharm Adjusts Capital Structure as Conditional Share Rights Lapse", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxPSHJSVHJ0UHVwODdIZENCTHQ0a0g3VENLQUtSdVZYUnN5TFBOTk03S21YSFJVRDdDM0swRnNBMkdLcWlpX1NUQWpOMnk4QURJS1BwQUdmN1psTDlOY0RUenktYnU0ZEZUM1p5bmx1WnJtRi1NdUZTT2tPMEh0ay1CNE9EU2I3SnQyQk15d1dFXzdjQ1pZNGRrVTBEWXFKcXhOdTVWMjJfWk9LQXNTclVpY1cxWmE2VGlaLWRTSkM1OA?oc=5", "source_name": "TipRanks", "published_at": "2026-07-06T05:20:36+00:00", "published_display": "06 Jul 2026 05:20", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cyclopharm (ASX:CYC): Healthcare Stock in Focus Amid Commercialisation Progress", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxQdEh0eWdEQ0dBTmo5M3hrb2xWSGpTOFlIckQydDFqUDNaVUNYYnNRT0FBOUdCcGZ4LUZVVzRhMXdkbjI4S1VDMExpY00tTm1oQ1YxZjRaaTVhRkRQUXF5Tnc1MFRyY0xfX0ZXdmJUem9SVkVKMGpvZzhCUi1hMVVKc2Nod0hkdmdicmszVHRNU0NfZnNPOGlZeWtBNm0zd1lqMEZtZUprM0w4d1JQeUZnYU5rUGw?oc=5", "source_name": "Kalkine", "published_at": "2026-07-01T07:00:00+00:00", "published_display": "01 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cyclopharm Slides as Healthcare Growth Stocks Face Pressure", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxOVUtXQmtpaHEyRjk1S20wUzBQVV9qaHJrNTBGTEFFa3VLSjVZTkdJdWRPbHRqRmtwVXlPTUtETUcxQnNNNnF0aWpuVGFyZVVIcDRHb3hxSmNVZUsxM1A5YXlvc3J3QzFORHVjLVdCMUVVbXl1S04wZGNNZjh1ZWlkaEh3azdzU3pRejQ1a3dJd21PTUtsVElndHZBajJCaXc?oc=5", "source_name": "Kalkine", "published_at": "2026-06-30T06:42:00+00:00", "published_display": "30 Jun 2026 06:42", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Will Cyclopharm\u2019s (ASX:CYC) UPHS Agreement Accelerate US Expansion?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxPQm1FWWJwRU8xTE95QTZabklkNGNkM29GOTEzUjlsRGlNX2tlN1UxNjR5dElfYjgzX1ZaVXFuMk15OTdCZ0VmZk1JU0h1VnBvZmhSd0ROQWxwd1V0WHpUakdrRWRDRzhXWTVocWNpMDNqMU9yYkg3RnVmcUJJM2ZpUm1vNHFoTEoyMDBvSHk2MTUwT0g4cE1NV0tQSkV1NWk0UDI4?oc=5", "source_name": "Kalkine", "published_at": "2026-03-23T07:00:00+00:00", "published_display": "23 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cyclopharm completes sale of cyclotron asset to strengthen focus on Technegas expansion", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxQandMU2kyejRzQm1jUW81b2Q4YjBDVUVfRFBvNDQ5WjlyRktWQUQzTmhfTDA0ekx3dmQ5XzVseGo5NlJIeWVzOFo0dnlvNV9obFY1TWprWFV5VFh5cmp1WDZWOEtMYWVmNEpzOFRyMWJPZXpySDR6Wk41bC1hLXlnNmV3cDctWUYyV2Q4bjVBM24zQ3ZodlRNMlhocWFkWkw0d2RMemFGSldSc0w0QVJMSnM1T0UzTFNLWGpnZEFtYlc?oc=5", "source_name": "BiotechDispatch", "published_at": "2025-11-12T08:00:00+00:00", "published_display": "12 Nov 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insights: Cyclopharm Ltd (ASX:CYC)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiUEFVX3lxTE1xV1ljZjd0NjlGbENYT2lQSmN0LWpDV05IcFcwVGZhS0xXUU5nNVR4clBmVkI3RWpoMVU0Tk5VMjRRS2FrVldPWDBrSlRLLW5J?oc=5", "source_name": "smallcaps.com.au", "published_at": "2025-10-30T14:12:47+00:00", "published_display": "30 Oct 2025 14:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cyclopharm (ASX:CYC): FDA approved for 2 years now, but a lawsuit from 4DX is the latest headache and cause for investor scepticism", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE1ocm1zWktPeUJzTGpicEZsWUlkMHV5RXQzaFpDc0ptcmtZalhPYklJb2dIOGQzZzZVck9RaWN6R1dXOHA0c3h4TVJqWC1GNlRENXlWMVFNUF9vZw?oc=5", "source_name": "Stocks Down Under", "published_at": "2025-10-08T07:00:00+00:00", "published_display": "08 Oct 2025 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rival biotechs 4D Medical, Cyclopharm in $24m court battle", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxQc0NpOHlNY0RicTc5NnFxSGNWUXU3a0Vka0pKVG5UZVZyazROZ3QxUTIzR1BNeGFKLVdQaXh2VjdHWENMNUItUzdfeWp1V0tMV00xVWJpWWgyY08wZnBxRVloS3lnWkxIMnBseFBOVUdFeTQ3dVFWUE5Gd0U5SUg1N0ItYy1EUF9ES2ducXd6ajZTM09SS1lyX04wU0lFWUFsaUdRS0dmbzlkTW9nSnNVeG53?oc=5", "source_name": "The Nightly", "published_at": "2025-10-06T07:00:00+00:00", "published_display": "06 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cyclopharm (ASX:CYC investor three-year losses grow to 43% as the stock sheds AU$19m this past week", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-09-04T07:00:00+00:00", "published_display": "04 Sep 2025 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cyclopharm Limited (ASX:CYC) Could Be Less Than A Year Away From Profitability", "summary": "", "url": "https://news.google.com/rss/articles/CBMizwFBVV95cUxOS2dXZ0hNWTVhWmh6ZnY0bTZsUDhRZk9pbmNrQ0FoYkYyekhwNkxCMnMwa1d1SzByLUxPTF9EelVCTzh2T19GNndmU3VqZkZPNUswSnU1STZBWFFZZjBibWpiRFl1eDk3N25aSElJUU5xTVJmM1doaXVJVzByZ1puVm9CTkxqSDNlUGxZT3V3OFdXSkVPYnR0eE5YeWNIelFYZUZwNFNmTG5GZTR0UTFzaU9oZWw1RHJYemdOTmJIVU1ZcTR2d2U1NkhYV0ZPNTjSAdQBQVVfeXFMTWVKQTRVU3J1cy1yXzhYVWlGbFFMbzNhV3VfN05MU0xGTHRpd2JsX3JnV3pXcGZkYW15YnVwX3dtM3NCVktVYVdQdFBFZEFsaUF1dkgwc1UxZF9ENFN0S2RlSFFweGdyb0xBYXRjeWk5d0RNS1p1M0hlR1J1ZDRGeGFJcldUS0FDRVBhR3lGX3Uya012RlhLMWctZ3VtUHJhaDlVYUtCWFgycmNJQWtsM2hyR2lzeUZNTHRQb2dvY0l2VWg3OHEwNnZYb3JqV1AtNE53UEk?oc=5", "source_name": "simplywall.st", "published_at": "2025-07-04T07:00:00+00:00", "published_display": "04 Jul 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biocurious: Lung imager Cyclopharm is breathing easy in the US market", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxOMDZoejRWX3ppLThObDEyMUs1YjF0bmNtdFNQZ29UWjFPNnNUUVpQTjM2bWNzbk1tOGs3cnBPZzF0ZFlaYkVkZ3c0QkRUYUVwVjhlMlltU1NEa2dxVWpYbzZ4emtvQ0NLR2lOV3VqN3J6Zkp1SEE2T084UGMwc1ZrcXktRnFlcnBHbDZXcVFiOHUzU3dLWnhsWERmeDhoTTFBYXNz?oc=5", "source_name": "Stockhead", "published_at": "2025-01-29T08:00:00+00:00", "published_display": "29 Jan 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Investors in Cyclopharm shares (ASX:CYC) just received some welcome clarity on the FDA approval process", "summary": "", "url": "https://news.google.com/rss/articles/CBMizwFBVV95cUxNMnptUUxTOG1ieURFdjh4VURsYXF6NldwYk9xNFQzRU1lZEJMblZKakVoMnFvYlIyVkwzMDZYendIZlRZUnJLZUczN1ZINVNHUDVfY0VnRHE5MmN0d3JNVzI4dHJTMXRqUlJzNEExS19qS3BSSTdCWjIxQXh0VmFrczluTzlmbm1mckFZRGFZUFVTMjg4QWdoWk1uM1ZMX3hUQ2pJVU9HajhaRmhkNVl1YU9ENDFJQjd0cmtjT0dWY0djVkhhYWNnLUVRX2FwSGM?oc=5", "source_name": "Stocks Down Under", "published_at": "2023-05-09T07:00:00+00:00", "published_display": "09 May 2023 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cyclopharm Limited (ASX: CYC) - Dividends", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigFBVV95cUxOaXYyNjZhSzBCMlB0SXZsTVZ5VFRzSTZYMTBTSV96bjdCNE5pbjc5WkpaYk1RMFExN1BjQ08zZG8tVDBGRkt2UnVqYVIyY0FuUzl2cWlRNlhjMTl3T0tfQXI3U2ZMdHVsb241b0U2d2VVbGxoMHhUdkpFWFJQQ2M4MkhaS3dQbDB0cXc?oc=5", "source_name": "intelligentinvestor.com.au", "published_at": "2019-10-01T04:30:30+00:00", "published_display": "01 Oct 2019 04:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cyclopharm Limited (ASX:CYC) - Shares, Dividends & News", "summary": "", "url": "https://news.google.com/rss/articles/CBMifEFVX3lxTE84MFdYaVZ5bl80bHFkeXZwQmhRUzRFM0tpM19yR3hBb1RkSUNJQlh4V0YxV2lKeDFaUnZ3UEdnZ0VROHhmb3R2X09SM1hlTEZ6M2dVM1VaUVNaQllkTWNPcVNpTWVrdEpzVmZtZ0c5MUlEelRhRi1JLTU0X0c?oc=5", "source_name": "intelligentinvestor.com.au", "published_at": "2019-09-23T12:27:22+00:00", "published_display": "23 Sep 2019 12:27", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CYC Stock Price and Chart \u2014 ASX:CYC", "summary": "", "url": "https://news.google.com/rss/articles/CBMiV0FVX3lxTE90WW14cjFfY052cnd4c1dzVDJsYl9FN0tKQlExdERZUUFEUHVEdnFXNnBlcWQzR3ZRczA2RlJVcUo1TXJXTF91dnZHc0NqTVoyRVY0NURmYw?oc=5", "source_name": "TradingView", "published_at": "2017-10-06T02:17:50+00:00", "published_display": "06 Oct 2017 02:17", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cyclopharm Ltd (ASX: CYC)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiUkFVX3lxTE1mUmtVMTluZ0VYWDB5aUdsQW0zX3N5RTBRaktLZ3ZDUlNPWWVUQ3Y5QlE2X0hBbUdyYXc5emNPZDZzNEkxRE1WSjBUZndYWmNPalE?oc=5", "source_name": "The Motley Fool Australia", "published_at": "2015-10-01T19:28:40+00:00", "published_display": "01 Oct 2015 19:28", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Cyclopharm Ltd (ASX:CYC) Jumps 25.77% as Shares Reach AUD 0.61", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxNYnFxbDZOSjZEZWdhMEJyT2EzVlZwVVdJTmxPWXdsRjVHVmI0SjEtOF9HZGRZVHQ0bF9McWNDQ2kxd24wSHo2QjBnLUUtXy1ybVlLSnNCVG1VbExHZE1WVlljWE9pcWNVdTJKc3RfVXB5SGowQ1UwZlR2QmpOWkptTFRPMzdiUWV4OFh4MENmMGk0aVZIUVBVVjNzZw?oc=5", "source_name": "Kalkine", "published_at": "2026-07-15T10:09:00+00:00", "published_display": "15 Jul 2026 10:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Australia's Cyclopharm secures 11-site agreement in US", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxPQjRVLXptcldNc21RRm9KUVVvSklTSHg0blZQOHJqYUM5OXJRN3pPbDdiUUhtNnJZZVVEZ09VeUhMYWlvYzJwa19IQmdhdERWcDIxQkxjWkVGNklNQnJ5ZlYxeDQyT1Q2dF9RVkFHdmRfcFNWYk5WU1dBNm4yTzJtc3JPVDI5dWJkcmVkdk8xcHowQzRz?oc=5", "source_name": "grafa.com", "published_at": "2026-07-15T06:02:00+00:00", "published_display": "15 Jul 2026 06:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cyclopharm (ASX:CYC) locks in 11-site University Hospitals rollout with no staged delay", "summary": "", "url": "https://news.google.com/rss/articles/CBMifEFVX3lxTE1Fd3R6ZGdNbkNhY01xV3QzZjRwVXdMVGtleFlhdTNxV08yZU45aE03d1NqX3YzQmhqMFdraFZ6cUlBQmtnYmdCS0o0cHdFUlFqSm84T1VZbVozWWJSS2NIOVJSUzQ4dUg4Y1I3eUxSQktNMFRaUVlmSjluU0M?oc=5", "source_name": "Stocks Down Under", "published_at": "2026-07-15T00:21:25+00:00", "published_display": "15 Jul 2026 00:21", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cyclopharm Adjusts Capital Structure as Conditional Share Rights Lapse", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxPSHJSVHJ0UHVwODdIZENCTHQ0a0g3VENLQUtSdVZYUnN5TFBOTk03S21YSFJVRDdDM0swRnNBMkdLcWlpX1NUQWpOMnk4QURJS1BwQUdmN1psTDlOY0RUenktYnU0ZEZUM1p5bmx1WnJtRi1NdUZTT2tPMEh0ay1CNE9EU2I3SnQyQk15d1dFXzdjQ1pZNGRrVTBEWXFKcXhOdTVWMjJfWk9LQXNTclVpY1cxWmE2VGlaLWRTSkM1OA?oc=5", "source_name": "TipRanks", "published_at": "2026-07-06T05:20:36+00:00", "published_display": "06 Jul 2026 05:20", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cyclopharm (ASX:CYC): Healthcare Stock in Focus Amid Commercialisation Progress", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxQdEh0eWdEQ0dBTmo5M3hrb2xWSGpTOFlIckQydDFqUDNaVUNYYnNRT0FBOUdCcGZ4LUZVVzRhMXdkbjI4S1VDMExpY00tTm1oQ1YxZjRaaTVhRkRQUXF5Tnc1MFRyY0xfX0ZXdmJUem9SVkVKMGpvZzhCUi1hMVVKc2Nod0hkdmdicmszVHRNU0NfZnNPOGlZeWtBNm0zd1lqMEZtZUprM0w4d1JQeUZnYU5rUGw?oc=5", "source_name": "Kalkine", "published_at": "2026-07-01T07:00:00+00:00", "published_display": "01 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cyclopharm Slides as Healthcare Growth Stocks Face Pressure", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxOVUtXQmtpaHEyRjk1S20wUzBQVV9qaHJrNTBGTEFFa3VLSjVZTkdJdWRPbHRqRmtwVXlPTUtETUcxQnNNNnF0aWpuVGFyZVVIcDRHb3hxSmNVZUsxM1A5YXlvc3J3QzFORHVjLVdCMUVVbXl1S04wZGNNZjh1ZWlkaEh3azdzU3pRejQ1a3dJd21PTUtsVElndHZBajJCaXc?oc=5", "source_name": "Kalkine", "published_at": "2026-06-30T06:42:00+00:00", "published_display": "30 Jun 2026 06:42", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Will Cyclopharm\u2019s (ASX:CYC) UPHS Agreement Accelerate US Expansion?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxPQm1FWWJwRU8xTE95QTZabklkNGNkM29GOTEzUjlsRGlNX2tlN1UxNjR5dElfYjgzX1ZaVXFuMk15OTdCZ0VmZk1JU0h1VnBvZmhSd0ROQWxwd1V0WHpUakdrRWRDRzhXWTVocWNpMDNqMU9yYkg3RnVmcUJJM2ZpUm1vNHFoTEoyMDBvSHk2MTUwT0g4cE1NV0tQSkV1NWk0UDI4?oc=5", "source_name": "Kalkine", "published_at": "2026-03-23T07:00:00+00:00", "published_display": "23 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cyclopharm completes sale of cyclotron asset to strengthen focus on Technegas expansion", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxQandMU2kyejRzQm1jUW81b2Q4YjBDVUVfRFBvNDQ5WjlyRktWQUQzTmhfTDA0ekx3dmQ5XzVseGo5NlJIeWVzOFo0dnlvNV9obFY1TWprWFV5VFh5cmp1WDZWOEtMYWVmNEpzOFRyMWJPZXpySDR6Wk41bC1hLXlnNmV3cDctWUYyV2Q4bjVBM24zQ3ZodlRNMlhocWFkWkw0d2RMemFGSldSc0w0QVJMSnM1T0UzTFNLWGpnZEFtYlc?oc=5", "source_name": "BiotechDispatch", "published_at": "2025-11-12T08:00:00+00:00", "published_display": "12 Nov 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insights: Cyclopharm Ltd (ASX:CYC)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiUEFVX3lxTE1xV1ljZjd0NjlGbENYT2lQSmN0LWpDV05IcFcwVGZhS0xXUU5nNVR4clBmVkI3RWpoMVU0Tk5VMjRRS2FrVldPWDBrSlRLLW5J?oc=5", "source_name": "smallcaps.com.au", "published_at": "2025-10-30T14:12:47+00:00", "published_display": "30 Oct 2025 14:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cyclopharm (ASX:CYC): FDA approved for 2 years now, but a lawsuit from 4DX is the latest headache and cause for investor scepticism", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE1ocm1zWktPeUJzTGpicEZsWUlkMHV5RXQzaFpDc0ptcmtZalhPYklJb2dIOGQzZzZVck9RaWN6R1dXOHA0c3h4TVJqWC1GNlRENXlWMVFNUF9vZw?oc=5", "source_name": "Stocks Down Under", "published_at": "2025-10-08T07:00:00+00:00", "published_display": "08 Oct 2025 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rival biotechs 4D Medical, Cyclopharm in $24m court battle", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxQc0NpOHlNY0RicTc5NnFxSGNWUXU3a0Vka0pKVG5UZVZyazROZ3QxUTIzR1BNeGFKLVdQaXh2VjdHWENMNUItUzdfeWp1V0tMV00xVWJpWWgyY08wZnBxRVloS3lnWkxIMnBseFBOVUdFeTQ3dVFWUE5Gd0U5SUg1N0ItYy1EUF9ES2ducXd6ajZTM09SS1lyX04wU0lFWUFsaUdRS0dmbzlkTW9nSnNVeG53?oc=5", "source_name": "The Nightly", "published_at": "2025-10-06T07:00:00+00:00", "published_display": "06 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cyclopharm (ASX:CYC investor three-year losses grow to 43% as the stock sheds AU$19m this past week", "summary": "", "url": "https://news.google.com/rss/articles/CBMizwFBVV95cUxOWG5VckxwU3NIaG9MYmUySHZRQWttN182QlBtaXBrSXVJbmZzYTk1N0FFZ1czb0VzV1ZmOVVXcC1pX2lLeV9FMTlJSUNheHY1LUk0TVluaV9FY092dmNGd3F3Ym45LUxMcWlGOXlmWkxNVGZFRUVqOG1WTHRyZExYdDlWY2phQ1BoaWw3YjIxQl9IS0ZLR3pKU3FNYXlMV09zMjY5QVBBNXpQZ3ZpQXBJd2xPWF80QzJvMVZENTRLUUsxMXNKc1pyRWt3a1FBMXfSAdQBQVVfeXFMUHlTb2hnZEFacW1DcnB6TVZKem1zcmU2UVFPeXljTlhRSUhJaDE5WFpmcVNPV3ItcEE5c2YyQm9rNGl3LXdScW9pVmtEYjJvTDFiRmJ0bkpZTGdaMEI2S2t0S21ocjZlQkVfX3JQcl9RSUdpYlJKWjRrOFVDU083WnBOOGQ2cHJsS3pxVGVkakRBMVY3akRjcW1XQ2R1Z3VfendWMFoyMW1WNlN4NFNRWFVCOVR2MHoySlBnMGtsVld5LS05dWUyNEhOZXVabHJwaEtaR1o?oc=5", "source_name": "simplywall.st", "published_at": "2025-09-04T07:00:00+00:00", "published_display": "04 Sep 2025 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cyclopharm Limited (ASX:CYC) Could Be Less Than A Year Away From Profitability", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-07-04T07:00:00+00:00", "published_display": "04 Jul 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biocurious: Lung imager Cyclopharm is breathing easy in the US market", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxOMDZoejRWX3ppLThObDEyMUs1YjF0bmNtdFNQZ29UWjFPNnNUUVpQTjM2bWNzbk1tOGs3cnBPZzF0ZFlaYkVkZ3c0QkRUYUVwVjhlMlltU1NEa2dxVWpYbzZ4emtvQ0NLR2lOV3VqN3J6Zkp1SEE2T084UGMwc1ZrcXktRnFlcnBHbDZXcVFiOHUzU3dLWnhsWERmeDhoTTFBYXNz?oc=5", "source_name": "Stockhead", "published_at": "2025-01-29T08:00:00+00:00", "published_display": "29 Jan 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Investors in Cyclopharm shares (ASX:CYC) just received some welcome clarity on the FDA approval process", "summary": "", "url": "https://news.google.com/rss/articles/CBMizwFBVV95cUxNMnptUUxTOG1ieURFdjh4VURsYXF6NldwYk9xNFQzRU1lZEJMblZKakVoMnFvYlIyVkwzMDZYendIZlRZUnJLZUczN1ZINVNHUDVfY0VnRHE5MmN0d3JNVzI4dHJTMXRqUlJzNEExS19qS3BSSTdCWjIxQXh0VmFrczluTzlmbm1mckFZRGFZUFVTMjg4QWdoWk1uM1ZMX3hUQ2pJVU9HajhaRmhkNVl1YU9ENDFJQjd0cmtjT0dWY0djVkhhYWNnLUVRX2FwSGM?oc=5", "source_name": "Stocks Down Under", "published_at": "2023-05-09T07:00:00+00:00", "published_display": "09 May 2023 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cyclopharm Limited (ASX: CYC) - Dividends", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigFBVV95cUxOaXYyNjZhSzBCMlB0SXZsTVZ5VFRzSTZYMTBTSV96bjdCNE5pbjc5WkpaYk1RMFExN1BjQ08zZG8tVDBGRkt2UnVqYVIyY0FuUzl2cWlRNlhjMTl3T0tfQXI3U2ZMdHVsb241b0U2d2VVbGxoMHhUdkpFWFJQQ2M4MkhaS3dQbDB0cXc?oc=5", "source_name": "intelligentinvestor.com.au", "published_at": "2019-10-01T04:30:30+00:00", "published_display": "01 Oct 2019 04:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cyclopharm Limited (ASX:CYC) - Shares, Dividends & News", "summary": "", "url": "https://news.google.com/rss/articles/CBMifEFVX3lxTE84MFdYaVZ5bl80bHFkeXZwQmhRUzRFM0tpM19yR3hBb1RkSUNJQlh4V0YxV2lKeDFaUnZ3UEdnZ0VROHhmb3R2X09SM1hlTEZ6M2dVM1VaUVNaQllkTWNPcVNpTWVrdEpzVmZtZ0c5MUlEelRhRi1JLTU0X0c?oc=5", "source_name": "intelligentinvestor.com.au", "published_at": "2019-09-23T12:27:22+00:00", "published_display": "23 Sep 2019 12:27", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CYC Stock Price and Chart \u2014 ASX:CYC", "summary": "", "url": "https://news.google.com/rss/articles/CBMiV0FVX3lxTE90WW14cjFfY052cnd4c1dzVDJsYl9FN0tKQlExdERZUUFEUHVEdnFXNnBlcWQzR3ZRczA2RlJVcUo1TXJXTF91dnZHc0NqTVoyRVY0NURmYw?oc=5", "source_name": "TradingView", "published_at": "2017-10-06T02:17:50+00:00", "published_display": "06 Oct 2017 02:17", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cyclopharm Ltd (ASX: CYC)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiUkFVX3lxTE1mUmtVMTluZ0VYWDB5aUdsQW0zX3N5RTBRaktLZ3ZDUlNPWWVUQ3Y5QlE2X0hBbUdyYXc5emNPZDZzNEkxRE1WSjBUZndYWmNPalE?oc=5", "source_name": "The Motley Fool Australia", "published_at": "2015-10-01T19:28:40+00:00", "published_display": "01 Oct 2015 19:28", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 81, "total_relevant": 19, "sentiment_summary": {"positive": 3, "negative": 2, "neutral": 14, "score": 51, "total": 19, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 91, "events": [{"event": "general", "label": "Market update", "weight": 9.35, "count": 17}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 1.1, "count": 2}], "positive_events": 3, "negative_events": 2}, "market_context": {"has_market_context": true, "latest_close": 0.53, "latest_week": "2026-07-10", "one_week_move": 6.1, "four_week_move": -8.7, "twelve_week_move": -27.1, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -1.167882, "market_dynamics_buy_signal": false, "relative_strength": -35.889815, "fair_value_gap": -63.1, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "negative", "expectation_probability": 39.0968, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+6.1% over one week, -8.7% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "positive", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 63, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Kalkine", "count": 4}, {"label": "Stocks Down Under", "count": 3}, {"label": "simplywall.st", "count": 2}, {"label": "intelligentinvestor.com.au", "count": 2}, {"label": "grafa.com", "count": 1}, {"label": "TipRanks", "count": 1}, {"label": "BiotechDispatch", "count": 1}, {"label": "smallcaps.com.au", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 19}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 17}, {"label": "Regulatory and legal", "count": 2}]}, "insights": [{"label": "Weighted tone", "value": "51/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "positive", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "91/100 classification confidence."}, {"label": "Company focus", "value": "19", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+6.1% over one week, -8.7% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Cyclopharm Ltd (ASX:CYC) Jumps 25.77% as Shares Reach AUD 0.61"}], "updated_at": "2026-07-17T06:16:58.708246+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}